Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Oxyphenbutazone | hsa00052 | Galactose metabolism | 4.27E-02 | 2 | P06280, O43451 | GLA, MGAM | More | | Oxyphenbutazone | hsa00220 | Arginine biosynthesis | 1.54E-02 | 2 | P05089, P49448 | ARG1, GLUD2 | More | | Oxyphenbutazone | hsa00310 | Lysine degradation | 2.59E-02 | 2 | Q96KQ7, P51648 | EHMT2, ALDH3A2 | More | | Oxyphenbutazone | hsa00500 | Starch and sucrose metabolism | 1.91E-04 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Oxyphenbutazone | hsa00512 | Mucin type O-glycan biosynthesis | 3.19E-03 | 3 | O95395, Q8N4A0, Q9NY28 | GCNT3, GALNT4, GALNT8 | More | | Oxyphenbutazone | hsa00520 | Amino sugar and nucleotide sugar metabolism | 2.24E-02 | 3 | Q16222, Q9Y223, P06865 | UAP1, GNE, HEXA | More | | Oxyphenbutazone | hsa00532 | Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate | 3.68E-02 | 1 | Q9Y2C2 | UST | More | | Oxyphenbutazone | hsa00533 | Glycosaminoglycan biosynthesis - keratan sulfate | 3.43E-02 | 1 | Q9NY97 | B3GNT2 | More | | Oxyphenbutazone | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Oxyphenbutazone | hsa00591 | Linoleic acid metabolism | 1.48E-03 | 1 | P11712 | CYP2C9 | More | | Oxyphenbutazone | hsa00600 | Sphingolipid metabolism | 2.77E-02 | 3 | Q9BX95, Q8TCT0, P15289 | SGPP1, CERK, ARSA | More | | Oxyphenbutazone | hsa00630 | Glyoxylate and dicarboxylate metabolism | 4.32E-05 | 2 | P40925, P15104 | MDH1, GLUL | More | | Oxyphenbutazone | hsa00730 | Thiamine metabolism | 1.55E-03 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Oxyphenbutazone | hsa00910 | Nitrogen metabolism | 2.93E-02 | 2 | P22748, P49448 | CA4, GLUD2 | More | | Oxyphenbutazone | hsa00920 | Sulfur metabolism | 4.01E-04 | 1 | Q16762 | TST | More | | Oxyphenbutazone | hsa00970 | Aminoacyl-tRNA biosynthesis | 2.24E-03 | 3 | O95363, P14868, Q15046 | FARS2, DARS, KARS | More | | Oxyphenbutazone | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Oxyphenbutazone | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Oxyphenbutazone | hsa00983 | Drug metabolism - other enzymes | 1.32E-03 | 3 | P04183, P32320, P05164 | TK1, CDA, MPO | More | | Oxyphenbutazone | hsa01040 | Biosynthesis of unsaturated fatty acids | 2.92E-02 | 2 | P22307, Q9H5J4 | SCP2, ELOVL6 | More | | Oxyphenbutazone | hsa01100 | Metabolic pathways | 4.43E-02 | 23 | Q9NR34, P05089, P32320, P22748, P55809, P06280, Q16875, O43286, O43451, P05186, P24666, Q9HCC0, P33121, P57054, Q9UNP4, Q9BX95, P32321, Q9BPW9, O75911, Q9UHY7, P43490, P46976, P06737 | MAN1C1, ARG1, CDA, CA4, OXCT1, GLA, PFKFB3, B4GALT5, MGAM, ALPL, ACP1, MCCC2, ACSL1, PIGP, ST3GAL5, SGPP1, DCTD, DHRS9, DHRS3, ENOPH1, PBEF1, GYG1, PYGL | More | | Oxyphenbutazone | hsa01210 | 2-Oxocarboxylic acid metabolism | 3.43E-02 | 1 | P50213 | IDH3A | More | | Oxyphenbutazone | hsa01522 | Endocrine resistance | 4.48E-02 | 4 | P22694, Q02750, Q9UM47, P46527 | PRKACB, MAP2K1, NOTCH3, CDKN1B | More | | Oxyphenbutazone | hsa01523 | Antifolate resistance | 3.80E-02 | 2 | Q92820, P04818 | GGH, TYMS | More | | Oxyphenbutazone | hsa03010 | Ribosome | 7.52E-03 | 2 | P46777, Q9UHA3 | RPL5, RSL24D1 | More | | Oxyphenbutazone | hsa03013 | RNA transport | 1.14E-03 | 13 | O14980, P52298, Q09161, O14893, P61326, Q7Z3B4, P35658, Q14152, O75822, P78345, Q14240, Q9Y6A5, P51114 | XPO1, NCBP2, NCBP1, GEMIN2, MAGOH, NUP54, NUP214, EIF3A, EIF3J, RPP38, EIF4A2, TACC3, FXR1 | More | | Oxyphenbutazone | hsa03040 | Spliceosome | 8.24E-08 | 14 | Q14562, O43143, O60508, P08579, P26368, Q13595, Q07955, Q01130, P84103, Q13243, P11142, Q9Y2W2, O43447, O75643 | DHX8, DHX15, CDC40, SNRPB2, U2AF2, TRA2A, SFRS1, SFRS2, SFRS3, SFRS5, HSPA8, WBP11, PPIH, ASCC3L1 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | Q14562 | DHX8 | ATP-dependent RNA helicase DHX8 | 0.775 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | O43143 | DHX15 | ATP-dependent RNA helicase DHX15 | 0.871 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | O43143 | DHX15 | ATP-dependent RNA helicase DHX15 | -0.76 | P35610 | SOAT1 | Sterol O-acyltransferase 1 | O60508 | CDC40 | Pre-mRNA-processing factor 17 | 0.76 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | O60508 | CDC40 | Pre-mRNA-processing factor 17 | 0.716 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | O60508 | CDC40 | Pre-mRNA-processing factor 17 | -0.812 | P35610 | SOAT1 | Sterol O-acyltransferase 1 | P08579 | SNRPB2 | U2 small nuclear ribonucleoprotein B'' | 0.787 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P08579 | SNRPB2 | U2 small nuclear ribonucleoprotein B'' | -0.822 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P26368 | U2AF2 | Splicing factor U2AF 65 kDa subunit | -0.751 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13595 | TRA2A | Transformer-2 protein homolog alpha | -0.74 | P35610 | SOAT1 | Sterol O-acyltransferase 1 | Q07955 | SFRS1 | Serine/arginine-rich splicing factor 1 | 0.712 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | Q07955 | SFRS1 | Serine/arginine-rich splicing factor 1 | 0.827 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q07955 | SFRS1 | Serine/arginine-rich splicing factor 1 | -0.749 | P35610 | SOAT1 | Sterol O-acyltransferase 1 | Q01130 | SFRS2 | Serine/arginine-rich splicing factor 2 | 0.822 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | Q01130 | SFRS2 | Serine/arginine-rich splicing factor 2 | 0.783 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q01130 | SFRS2 | Serine/arginine-rich splicing factor 2 | -0.798 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P84103 | SFRS3 | Serine/arginine-rich splicing factor 3 | -0.773 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | Q13243 | SFRS5 | Serine/arginine-rich splicing factor 5 | 0.943 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13243 | SFRS5 | Serine/arginine-rich splicing factor 5 | -0.822 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P11142 | HSPA8 | Heat shock cognate 71 kDa protein | 0.876 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P11142 | HSPA8 | Heat shock cognate 71 kDa protein | -0.802 | P35610 | SOAT1 | Sterol O-acyltransferase 1 | Q9Y2W2 | WBP11 | WW domain-binding protein 11 | 0.711 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q9Y2W2 | WBP11 | WW domain-binding protein 11 | -0.743 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | O43447 | PPIH | Peptidyl-prolyl cis-trans isomerase H | -0.766 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | O75643 | ASCC3L1 | U5 small nuclear ribonucleoprotein 200 kDa helicase | -0.745 |
| Oxyphenbutazone | hsa03050 | Proteasome | 1.79E-03 | 1 | P55036 | PSMD4 | More | | Oxyphenbutazone | hsa03060 | Protein export | 1.90E-02 | 2 | Q15070, O76094 | OXA1L, SRP72 | More | | Oxyphenbutazone | hsa03450 | Non-homologous end-joining | 4.21E-02 | 1 | P13010 | XRCC5 | More | | Oxyphenbutazone | hsa04014 | Ras signaling pathway | 9.87E-06 | 17 | Q02750, P42338, P20827, Q15389, Q9NRA1, P49767, Q13009, P17252, Q7LDG7, P21359, P0DP23, P62873, P62879, P63218, P50151, P19174, P22694 | MAP2K1, PIK3CB, EFNA1, ANGPT1, PDGFC, VEGFC, TIAM1, PRKCA, RASGRP2, NF1, CALM1, GNB1, GNB2, GNG5, GNG10, PLCG1, PRKACB | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
Q13315 | ATM | Serine-protein kinase ATM | Q02750 | MAP2K1 | Dual specificity mitogen-activated protein kinase kinase 1 | -0.797 | P35610 | SOAT1 | Sterol O-acyltransferase 1 | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.813 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | 0.777 | P35610 | SOAT1 | Sterol O-acyltransferase 1 | P20827 | EFNA1 | Ephrin-A1 | -0.763 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P20827 | EFNA1 | Ephrin-A1 | 0.715 | Q13315 | ATM | Serine-protein kinase ATM | Q15389 | ANGPT1 | Angiopoietin-1 | 0.726 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | Q9NRA1 | PDGFC | Platelet-derived growth factor C | -0.776 | P35610 | SOAT1 | Sterol O-acyltransferase 1 | P49767 | VEGFC | Vascular endothelial growth factor C | -0.711 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P49767 | VEGFC | Vascular endothelial growth factor C | 0.743 | P35610 | SOAT1 | Sterol O-acyltransferase 1 | Q13009 | TIAM1 | Rho guanine nucleotide exchange factor TIAM1 | -0.71 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | Q13009 | TIAM1 | Rho guanine nucleotide exchange factor TIAM1 | -0.746 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13009 | TIAM1 | Rho guanine nucleotide exchange factor TIAM1 | 0.706 | Q13315 | ATM | Serine-protein kinase ATM | P17252 | PRKCA | Protein kinase C alpha type | 0.739 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q7LDG7 | RASGRP2 | RAS guanyl-releasing protein 2 | 0.704 | Q13315 | ATM | Serine-protein kinase ATM | P21359 | NF1 | Neurofibromin | 0.762 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P0DP23 | CALM1 | Calmodulin-1 | 0.775 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P62873 | GNB1 | Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 | 0.82 | Q13315 | ATM | Serine-protein kinase ATM | P62879 | GNB2 | Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2 | -0.716 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | -0.703 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.941 | P35610 | SOAT1 | Sterol O-acyltransferase 1 | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | -0.838 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | -0.704 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.948 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.869 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | -0.766 | Q13315 | ATM | Serine-protein kinase ATM | P22694 | PRKACB | cAMP-dependent protein kinase catalytic subunit beta | 0.858 |
| Oxyphenbutazone | hsa04015 | Rap1 signaling pathway | 1.79E-02 | 8 | P20827, P49767, Q96FS4, P11215, Q13009, Q7LDG7, P42338, P19174 | EFNA1, VEGFC, SIPA1, ITGAM, TIAM1, RASGRP2, PIK3CB, PLCG1 | More | | Oxyphenbutazone | hsa04060 | Cytokine-cytokine receptor interaction | 5.39E-03 | 10 | P27930, P08476, Q13651, Q9HBE5, Q9UBD3, P47992, P01375, P09341, P18510, Q93038 | IL1R2, INHBA, IL10RA, IL21R, XCL2, XCL1, TNF, CXCL1, IL1RN, TNFRSF25 | More | | Oxyphenbutazone | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 4.34E-02 | 5 | P09341, P47992, Q9UBD3, Q13651, P01375 | CXCL1, XCL1, XCL2, IL10RA, TNF | More | | Oxyphenbutazone | hsa04062 | Chemokine signaling pathway | 6.84E-05 | 14 | P09769, P07948, P42338, P19174, P62873, P63218, P50151, P43250, Q7LDG7, Q13009, P14598, P42224, P25963, Q8WYR1 | FGR, LYN, PIK3CB, PLCG1, GNB1, GNG5, GNG10, GRK6, RASGRP2, TIAM1, NCF1, STAT1, NFKBIA, PIK3R5 | More | | Oxyphenbutazone | hsa04064 | NF-kappa B signaling pathway | 5.33E-07 | 16 | P10415, Q13489, P25963, P51617, O00463, P14778, P01375, Q04759, Q9UDY8, Q13077, Q16548, P06239, Q8WV28, Q13315, P24522, P09341 | BCL2, BIRC3, NFKBIA, IRAK1, TRAF5, IL1R1, TNF, PRKCQ, MALT1, TRAF1, BCL2A1, LCK, BLNK, ATM, GADD45A, CXCL1 | More | | Oxyphenbutazone | hsa04066 | HIF-1 signaling pathway | 4.48E-02 | 4 | P17252, Q15389, Q02750, P46527 | PRKCA, ANGPT1, MAP2K1, CDKN1B | More | | Oxyphenbutazone | hsa04070 | Phosphatidylinositol signaling system | 2.93E-02 | 4 | P19174, P0DP23, P23743, P27987 | PLCG1, CALM1, DGKA, ITPKB | More | | Oxyphenbutazone | hsa04071 | Sphingolipid signaling pathway | 1.05E-04 | 8 | P17252, P21453, Q9H228, P01375, Q13362, Q9BX95, P10415, Q9UQC2 | PRKCA, S1PR1, EDG8, TNF, PPP2R5C, SGPP1, BCL2, GAB2 | More | | Oxyphenbutazone | hsa04080 | Neuroactive ligand-receptor interaction | 1.18E-02 | 7 | P08311, Q15722, P21453, Q9H228, O00398, P21462, P21730 | CTSG, LTB4R, S1PR1, EDG8, P2RY10, FPR1, C5AR1 | More | | Oxyphenbutazone | hsa04110 | Cell cycle | 6.80E-03 | 6 | P06493, O75293, P30304, P33981, P42773, P01106 | CDK1, GADD45B, CDC25A, TTK, CDKN2C, MYC | More | | Oxyphenbutazone | hsa04115 | p53 signaling pathway | 3.57E-02 | 5 | P24522, Q13315, Q53FA7, O95067, P10415 | GADD45A, ATM, TP53I3, CCNB2, BCL2 | More | | Oxyphenbutazone | hsa04122 | Sulfur relay system | 4.01E-04 | 1 | Q16762 | TST | More | | Oxyphenbutazone | hsa04136 | Autophagy - other | 3.53E-02 | 1 | O94817 | ATG12 | More | | Oxyphenbutazone | hsa04141 | Protein processing in endoplasmic reticulum | 7.69E-04 | 9 | P30101, P07384, O95487, P60604, P11142, P08238, O95816, Q9H173, Q9UNL2 | PDIA3, CAPN1, SEC24B, UBE2G2, HSPA8, HSP90AB1, BAG2, SIL1, SSR3 | More | | Oxyphenbutazone | hsa04144 | Endocytosis | 4.10E-02 | 3 | O75351, P62491, Q14161 | VPS4B, RAB11A, GIT2 | More | | Oxyphenbutazone | hsa04145 | Phagosome | 5.26E-04 | 11 | P11215, Q15080, P14598, Q71U36, Q13509, P68371, Q13488, P05164, O60603, P35443, P13765 | ITGAM, NCF4, NCF1, TUBA1A, TUBB3, TUBB2C, TCIRG1, MPO, TLR2, THBS4, HLA-DOB | More | | Oxyphenbutazone | hsa04151 | PI3K-Akt signaling pathway | 1.89E-03 | 12 | P42338, P43657, P20827, P49767, P08238, Q8WYR1, P63218, P50151, O15335, Q13751, P14784, P30281 | PIK3CB, P2RY5, EFNA1, VEGFC, HSP90AB1, PIK3R5, GNG5, GNG10, CHAD, LAMB3, IL2RB, CCND3 | More | | Oxyphenbutazone | hsa04210 | Apoptosis | 1.52E-02 | 9 | Q13315, P10415, Q13489, P25963, P01375, P24522, Q16548, Q13077, Q14643 | ATM, BCL2, BIRC3, NFKBIA, TNF, GADD45A, BCL2A1, TRAF1, ITPR1 | More | | Oxyphenbutazone | hsa04215 | Apoptosis - multiple species | 1.56E-02 | 2 | Q13489, P10415 | BIRC3, BCL2 | More | | Oxyphenbutazone | hsa04218 | Cellular senescence | 4.79E-02 | 4 | P01106, O75293, P30304, P06493 | MYC, GADD45B, CDC25A, CDK1 | More | | Oxyphenbutazone | hsa04340 | Hedgehog signaling pathway | 1.80E-02 | 4 | P49841, P22694, Q13635, P10415 | GSK3B, PRKACB, PTCH1, BCL2 | More | | Oxyphenbutazone | hsa04360 | Axon guidance | 2.74E-03 | 8 | P16333, P20827, O95631, P42338, P07332, P23528, P19174, Q06124 | NCK1, EFNA1, NTN1, PIK3CB, FES, CFL1, PLCG1, PTPN11 | More | | Oxyphenbutazone | hsa04371 | Apelin signaling pathway | 3.84E-05 | 10 | P62873, P63218, P50151, Q8WYR1, Q13370, Q14814, Q14344, Q13485, P84022, P0DP23 | GNB1, GNG5, GNG10, PIK3R5, PDE3B, MEF2D, GNA13, SMAD4, SMAD3, CALM1 | More | | Oxyphenbutazone | hsa04380 | Osteoclast differentiation | 1.02E-02 | 6 | Q9UQC2, Q16539, P14778, O75015, P01375, Q8N149 | GAB2, MAPK14, IL1R1, FCGR3B, TNF, LILRA2 | More | | Oxyphenbutazone | hsa04390 | Hippo signaling pathway | 2.08E-02 | 3 | P84022, Q13485, Q13489 | SMAD3, SMAD4, BIRC3 | More | | Oxyphenbutazone | hsa04512 | ECM-receptor interaction | 2.00E-02 | 2 | P07359, P08514 | GP1BA, ITGA2B | More | | Oxyphenbutazone | hsa04514 | Cell adhesion molecules | 2.05E-03 | 2 | P16109, O00501 | SELP, CLDN5 | More | | Oxyphenbutazone | hsa04530 | Tight junction | 1.88E-04 | 8 | P63261, P16989, P56750, O00501, Q9Y478, Q92974, Q14247, P24844 | ACTG1, CSDA, CLDN17, CLDN5, PRKAB1, ARHGEF2, CTTN, MYL9 | More | | Oxyphenbutazone | hsa04540 | Gap junction | 6.95E-04 | 7 | P17252, P22694, Q13509, P68371, Q71U36, Q02750, Q9NRA1 | PRKCA, PRKACB, TUBB3, TUBB2C, TUBA1A, MAP2K1, PDGFC | More | | Oxyphenbutazone | hsa04610 | Complement and coagulation cascades | 3.16E-03 | 2 | P00734, P0C0L4 | F2, C4A | More | | Oxyphenbutazone | hsa04611 | Platelet activation | 2.25E-04 | 4 | P08514, Q15746, Q8WYR1, P07359 | ITGA2B, MYLK, PIK3R5, GP1BA | More | | Oxyphenbutazone | hsa04612 | Antigen processing and presentation | 9.89E-03 | 7 | P13765, P48382, P26715, P26717, Q13241, P01732, P01375 | HLA-DOB, RFX5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | | Oxyphenbutazone | hsa04613 | Neutrophil extracellular trap formation | 1.28E-05 | 21 | P17252, P16109, O60603, P05164, P08246, Q9UM07, Q6FI13, Q99878, Q93077, P62807, O60814, P68431, P14598, Q15080, P20160, P08311, P49913, P21730, P08514, P21462, P07359 | PRKCA, SELP, TLR2, MPO, ELA2, PADI4, H2AC18; H2AC19, H2AC14, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF1, NCF4, AZU1, CTSG, CAMP, C5AR1, ITGA2B, FPR1, GP1BA | More | | Oxyphenbutazone | hsa04621 | NOD-like receptor signaling pathway | 3.10E-03 | 11 | Q14643, P25963, Q13489, Q9H1Y0, P43490, O00463, P10415, Q05823, P01375, P49913, P12838 | ITPR1, NFKBIA, BIRC3, ATG5, PBEF1, TRAF5, BCL2, RNASEL, TNF, CAMP, DEFA4 | More | | Oxyphenbutazone | hsa04623 | Cytosolic DNA-sensing pathway | 2.59E-02 | 2 | P01568, P25963 | IFNA21, NFKBIA | More | | Oxyphenbutazone | hsa04625 | C-type lectin receptor signaling pathway | 3.87E-02 | 4 | Q9ULY5, P20749, P01375, Q16539 | CLEC4E, BCL3, TNF, MAPK14 | More | | Oxyphenbutazone | hsa04640 | Hematopoietic cell lineage | 6.05E-03 | 10 | P21926, P27930, P25063, P07766, P09693, P01732, P01730, P09564, P13765, P01375 | CD9, IL1R2, CD24, CD3E, CD3G, CD8A, CD4, CD7, HLA-DOB, TNF | More | | Oxyphenbutazone | hsa04650 | Natural killer cell mediated cytotoxicity | 2.77E-04 | 9 | P01375, P06239, O60880, P20963, Q13241, P26718, O14931, P26717, P26715 | TNF, LCK, SH2D1A, CD247, KLRD1, KLRK1, NCR3, KLRC2, KLRC1 | More | | Oxyphenbutazone | hsa04657 | IL-17 signaling pathway | 1.10E-04 | 7 | O00463, Q16539, P49841, P09341, P14780, P80188, P01375 | TRAF5, MAPK14, GSK3B, CXCL1, MMP9, LCN2, TNF | More | | Oxyphenbutazone | hsa04658 | Th1 and Th2 cell differentiation | 2.48E-05 | 10 | Q04759, P07766, P20963, P09693, P06239, Q14765, P23771, Q9UL17, P13765, Q13761 | PRKCQ, CD3E, CD247, CD3G, LCK, STAT4, GATA3, TBX21, HLA-DOB, RUNX3 | More | | Oxyphenbutazone | hsa04659 | Th17 cell differentiation | 1.08E-06 | 17 | P25963, Q04759, P19174, P06239, P42224, P14784, P13765, P14778, Q9HBE5, Q9UL17, P23771, P84022, Q13485, P08238, P07766, P09693, P20963 | NFKBIA, PRKCQ, PLCG1, LCK, STAT1, IL2RB, HLA-DOB, IL1R1, IL21R, TBX21, GATA3, SMAD3, SMAD4, HSP90AB1, CD3E, CD3G, CD247 | More | | Oxyphenbutazone | hsa04660 | T cell receptor signaling pathway | 1.76E-05 | 13 | P01375, P25963, Q9UDY8, Q04759, P10747, O95267, Q08881, P07766, P20963, P09693, P01732, Q13191, P06239 | TNF, NFKBIA, MALT1, PRKCQ, CD28, RASGRP1, ITK, CD3E, CD247, CD3G, CD8A, CBLB, LCK | More | | Oxyphenbutazone | hsa04662 | B cell receptor signaling pathway | 9.03E-05 | 5 | P42338, P60033, P07948, P21854, Q8N149 | PIK3CB, CD81, LYN, CD72, LILRA2 | More | | Oxyphenbutazone | hsa04664 | Fc epsilon RI signaling pathway | 3.09E-06 | 8 | P01375, P04141, Q16539, P42338, Q9UQC2, P07948, P19174, P09917 | TNF, CSF2, MAPK14, PIK3CB, GAB2, LYN, PLCG1, ALOX5 | More | | Oxyphenbutazone | hsa04668 | TNF signaling pathway | 1.83E-03 | 8 | P01375, O00463, Q13489, Q16539, P25963, P20749, Q13077, P14780 | TNF, TRAF5, BIRC3, MAPK14, NFKBIA, BCL3, TRAF1, MMP9 | More | | Oxyphenbutazone | hsa04670 | Leukocyte transendothelial migration | 4.20E-02 | 7 | P14780, Q96A32, P17252, P14598, Q15080, Q08881, P42681 | MMP9, MYLPF, PRKCA, NCF1, NCF4, ITK, TXK | More | | Oxyphenbutazone | hsa04713 | Circadian entrainment | 2.18E-02 | 4 | P0DP23, P62873, P63218, P50151 | CALM1, GNB1, GNG5, GNG10 | More | | Oxyphenbutazone | hsa04714 | Thermogenesis | 1.25E-02 | 3 | P15336, P63261, Q9Y478 | ATF2, ACTG1, PRKAB1 | More | | Oxyphenbutazone | hsa04720 | Long-term potentiation | 1.09E-02 | 4 | P17252, P51812, P22694, Q02750 | PRKCA, RPS6KA3, PRKACB, MAP2K1 | More | | Oxyphenbutazone | hsa04724 | Glutamatergic synapse | 1.27E-03 | 5 | P43003, P62873, P63218, P50151, P15104 | SLC1A3, GNB1, GNG5, GNG10, GLUL | More | | Oxyphenbutazone | hsa04725 | Cholinergic synapse | 2.43E-02 | 4 | P22694, P17252, P62879, Q02750 | PRKACB, PRKCA, GNB2, MAP2K1 | More | | Oxyphenbutazone | hsa04726 | Serotonergic synapse | 2.16E-03 | 8 | P22694, P17252, P62873, P62879, P63218, P50151, P09917, Q02750 | PRKACB, PRKCA, GNB1, GNB2, GNG5, GNG10, ALOX5, MAP2K1 | More | | Oxyphenbutazone | hsa04727 | GABAergic synapse | 4.07E-04 | 8 | P62873, P62879, P63218, P50151, P15104, P22694, O60296, P17252 | GNB1, GNB2, GNG5, GNG10, GLUL, PRKACB, TRAK2, PRKCA | More | | Oxyphenbutazone | hsa04730 | Long-term depression | 4.86E-02 | 2 | Q14344, P07948 | GNA13, LYN | More | | Oxyphenbutazone | hsa04744 | Phototransduction | 9.21E-03 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | | Oxyphenbutazone | hsa04919 | Thyroid hormone signaling pathway | 2.22E-02 | 5 | P17252, Q02750, P22694, Q12778, Q9UM47 | PRKCA, MAP2K1, PRKACB, FOXO1, NOTCH3 | More | | Oxyphenbutazone | hsa04920 | Adipocytokine signaling pathway | 4.71E-03 | 6 | P25963, Q06124, P33121, Q9Y478, Q04759, P01375 | NFKBIA, PTPN11, ACSL1, PRKAB1, PRKCQ, TNF | More | | Oxyphenbutazone | hsa04921 | Oxytocin signaling pathway | 4.91E-02 | 2 | Q15746, Q8WYR1 | MYLK, PIK3R5 | More | | Oxyphenbutazone | hsa04924 | Renin secretion | 3.64E-02 | 3 | P22694, P07550, Q14643 | PRKACB, ADRB2, ITPR1 | More | | Oxyphenbutazone | hsa04928 | Parathyroid hormone synthesis, secretion and action | 4.48E-02 | 4 | P22694, Q02750, P17252, Q9Y5Q3 | PRKACB, MAP2K1, PRKCA, MAFB | More | | Oxyphenbutazone | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 2.11E-03 | 6 | P84022, Q13485, P10415, P42338, P49767, P19174 | SMAD3, SMAD4, BCL2, PIK3CB, VEGFC, PLCG1 | More | | Oxyphenbutazone | hsa04962 | Vasopressin-regulated water reabsorption | 1.80E-02 | 2 | P62491, P46459 | RAB11A, NSF | More | | Oxyphenbutazone | hsa04964 | Proximal tubule bicarbonate reclamation | 2.93E-02 | 2 | P22748, P49448 | CA4, GLUD2 | More | | Oxyphenbutazone | hsa04970 | Salivary secretion | 4.89E-03 | 4 | P22694, Q14643, P17252, P49913 | PRKACB, ITPR1, PRKCA, CAMP | More | | Oxyphenbutazone | hsa04975 | Fat digestion and absorption | 3.43E-02 | 1 | O14494 | PLPP1 | More | | Oxyphenbutazone | hsa05012 | Parkinson disease | 1.77E-02 | 6 | P60604, P19174, P0DP23, Q71U36, Q13509, P68371 | UBE2G2, PLCG1, CALM1, TUBA1A, TUBB3, TUBB2C | More | | Oxyphenbutazone | hsa05032 | Morphine addiction | 2.18E-02 | 4 | P62873, P63218, P50151, Q13370 | GNB1, GNG5, GNG10, PDE3B | More | | Oxyphenbutazone | hsa05034 | Alcoholism | 2.89E-03 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Oxyphenbutazone | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 6.88E-04 | 8 | Q16539, P25963, Q13488, P09341, P19174, P25024, P25025, P07948 | MAPK14, NFKBIA, TCIRG1, CXCL1, PLCG1, CXCR1, CXCR2, LYN | More | | Oxyphenbutazone | hsa05130 | Pathogenic Escherichia coli infection | 1.44E-03 | 10 | Q71U36, P16333, Q92974, Q13509, P68371, P63261, Q14344, P25963, Q06124, O95487 | TUBA1A, NCK1, ARHGEF2, TUBB3, TUBB2C, ACTG1, GNA13, NFKBIA, PTPN11, SEC24B | More | | Oxyphenbutazone | hsa05131 | Shigellosis | 3.34E-02 | 11 | P01375, P25963, O00463, Q04759, Q9UDY8, Q9H1Y0, Q14643, Q12778, Q13315, P10415, Q96A32 | TNF, NFKBIA, TRAF5, PRKCQ, MALT1, ATG5, ITPR1, FOXO1, ATM, BCL2, MYLPF | More | | Oxyphenbutazone | hsa05132 | Salmonella infection | 2.79E-04 | 16 | P51617, P25963, P01375, P08238, Q9UJU2, Q13489, P10415, O75369, Q96A32, O60603, Q9BQS8, Q13561, Q71U36, Q13509, P68371, P49754 | IRAK1, NFKBIA, TNF, HSP90AB1, LEF1, BIRC3, BCL2, FLNB, MYLPF, TLR2, FYCO1, DCTN2, TUBA1A, TUBB3, TUBB2C, VPS41 | More | | Oxyphenbutazone | hsa05133 | Pertussis | 2.24E-02 | 2 | P0DP23, P0C0L4 | CALM1, C4A | More | | Oxyphenbutazone | hsa05134 | Legionellosis | 4.75E-02 | 3 | P25963, P11215, P11142 | NFKBIA, ITGAM, HSPA8 | More | | Oxyphenbutazone | hsa05140 | Leishmaniasis | 1.31E-04 | 12 | O75015, P14598, P11215, P42224, P13765, O60603, P25963, P01375, P49006, Q16539, P51617, Q15080 | FCGR3B, NCF1, ITGAM, STAT1, HLA-DOB, TLR2, NFKBIA, TNF, MARCKSL1, MAPK14, IRAK1, NCF4 | More | | Oxyphenbutazone | hsa05143 | African trypanosomiasis | 4.81E-02 | 2 | P69905, P68871 | HBA2, HBB | More | | Oxyphenbutazone | hsa05144 | Malaria | 4.92E-02 | 4 | O60603, P01375, P35443, P26718 | TLR2, TNF, THBS4, KLRK1 | More | | Oxyphenbutazone | hsa05145 | Toxoplasmosis | 4.06E-03 | 7 | P51617, P25963, P01375, P10415, Q13489, P13765, O60603 | IRAK1, NFKBIA, TNF, BCL2, BIRC3, HLA-DOB, TLR2 | More | | Oxyphenbutazone | hsa05146 | Amoebiasis | 1.08E-03 | 9 | P09341, P14778, P27930, P01375, O60603, P05089, P22694, P12814, P08311 | CXCL1, IL1R1, IL1R2, TNF, TLR2, ARG1, PRKACB, ACTN1, CTSG | More | | Oxyphenbutazone | hsa05150 | Staphylococcus aureus infection | 3.32E-02 | 2 | Q14532, P16109 | KRT32, SELP | More | | Oxyphenbutazone | hsa05152 | Tuberculosis | 2.07E-02 | 9 | Q13488, P48382, O60603, P01375, P10415, P13765, P49913, Q9UDY8, P51617 | TCIRG1, RFX5, TLR2, TNF, BCL2, HLA-DOB, CAMP, MALT1, IRAK1 | More | | Oxyphenbutazone | hsa05161 | Hepatitis B | 1.61E-03 | 10 | P17252, P14780, P25963, Q13485, P01375, P10415, P84022, P51617, O60603, Q14765 | PRKCA, MMP9, NFKBIA, SMAD4, TNF, BCL2, SMAD3, IRAK1, TLR2, STAT4 | More | | Oxyphenbutazone | hsa05163 | Human cytomegalovirus infection | 3.67E-05 | 16 | P01375, P25963, P62873, P63218, P50151, Q14643, P0DP23, Q14344, P49841, P14778, P25025, Q16539, P04637, O00463, P30101, P01568 | TNF, NFKBIA, GNB1, GNG5, GNG10, ITPR1, CALM1, GNA13, GSK3B, IL1R1, CXCR2, MAPK14, TP53, TRAF5, PDIA3, IFNA21 | More | | Oxyphenbutazone | hsa05165 | Human papillomavirus infection | 4.71E-03 | 10 | P46527, Q02750, P35443, Q92796, Q05086, Q9UM47, P22694, Q13362, Q12778, Q13315 | CDKN1B, MAP2K1, THBS4, DLG3, UBE3A, NOTCH3, PRKACB, PPP2R5C, FOXO1, ATM | More | | Oxyphenbutazone | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 8.62E-05 | 10 | P01568, P42224, P25963, P62873, P63218, P50151, P19174, P07948, P04141, P0DP23 | IFNA21, STAT1, NFKBIA, GNB1, GNG5, GNG10, PLCG1, LYN, CSF2, CALM1 | More | | Oxyphenbutazone | hsa05168 | Herpes simplex virus 1 infection | 3.79E-02 | 9 | P25963, P01568, P42224, Q07955, Q01130, Q13243, P30101, Q13398, O75820 | NFKBIA, IFNA21, STAT1, SFRS1, SFRS2, SFRS5, PDIA3, ZNF211, ZNF189 | More | | Oxyphenbutazone | hsa05170 | Human immunodeficiency virus 1 infection | 4.52E-05 | 20 | P62873, P63218, P50151, P0DP23, P01375, P17252, O00463, P30101, Q14643, P01568, P51617, P25963, O60603, Q13315, O95067, P19174, P10415, Q13619, Q93034, Q9Y6Q5 | GNB1, GNG5, GNG10, CALM1, TNF, PRKCA, TRAF5, PDIA3, ITPR1, IFNA21, IRAK1, NFKBIA, TLR2, ATM, CCNB2, PLCG1, BCL2, CUL4A, CUL5, AP1M2 | More | | Oxyphenbutazone | hsa05200 | Pathways in cancer | 8.64E-05 | 23 | Q13751, P42338, P08238, P42224, P25963, P19174, P43246, P84022, Q13485, P20585, Q13547, P30281, P49767, P43657, P62873, P63218, P50151, Q14344, Q7LDG7, O75293, P0DP23, P01568, P14784 | LAMB3, PIK3CB, HSP90AB1, STAT1, NFKBIA, PLCG1, MSH2, SMAD3, SMAD4, MSH3, HDAC1, CCND3, VEGFC, P2RY5, GNB1, GNG5, GNG10, GNA13, RASGRP2, GADD45B, CALM1, IFNA21, IL2RB | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13751 | LAMB3 | Laminin subunit beta-3 | 0.844 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | 0.777 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | 1 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | -0.823 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | 0.783 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P25963 | NFKBIA | NF-kappa-B inhibitor alpha | 0.818 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.869 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | -0.766 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P43246 | MSH2 | DNA mismatch repair protein Msh2 | 0.816 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P43246 | MSH2 | DNA mismatch repair protein Msh2 | -0.811 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P84022 | SMAD3 | Mothers against decapentaplegic homolog 3 | -0.77 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P84022 | SMAD3 | Mothers against decapentaplegic homolog 3 | 0.725 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.746 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P20585 | MSH3 | DNA mismatch repair protein Msh3 | 0.825 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13547 | HDAC1 | Histone deacetylase 1 | -0.754 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P30281 | CCND3 | G1/S-specific cyclin-D3 | 0.743 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P49767 | VEGFC | Vascular endothelial growth factor C | 0.743 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | -0.735 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P62873 | GNB1 | Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 | 0.82 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | -0.703 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.941 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | -0.704 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.948 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | Q14344 | GNA13 | Guanine nucleotide-binding protein subunit alpha-13 | -0.756 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q14344 | GNA13 | Guanine nucleotide-binding protein subunit alpha-13 | 0.87 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q7LDG7 | RASGRP2 | RAS guanyl-releasing protein 2 | 0.704 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | O75293 | GADD45B | Growth arrest and DNA damage-inducible protein GADD45 beta | -0.742 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | O75293 | GADD45B | Growth arrest and DNA damage-inducible protein GADD45 beta | 0.731 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P0DP23 | CALM1 | Calmodulin-1 | 0.775 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P01568 | IFNA21 | Interferon alpha-21 | -0.733 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.717 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P14784 | IL2RB | Interleukin-2 receptor subunit beta | -0.835 |
| Oxyphenbutazone | hsa05202 | Transcriptional misregulation in cancer | 7.13E-07 | 17 | Q12778, Q15532, Q13315, P14780, P27930, P14923, Q15744, Q16548, Q13489, Q13077, P46527, P35226, P05164, P12838, P08246, Q9C0K0, P24522 | FOXO1, SS18, ATM, MMP9, IL1R2, JUP, CEBPE, BCL2A1, BIRC3, TRAF1, CDKN1B, BMI1, MPO, DEFA4, ELA2, BCL11B, GADD45A | More | | Oxyphenbutazone | hsa05203 | Viral carcinogenesis | 4.52E-03 | 4 | Q15283, P62807, P33778, O60814 | RASA2, HIST1H2BC, H2BC3, H2BC12 | More | | Oxyphenbutazone | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Oxyphenbutazone | hsa05206 | MicroRNAs in cancer | 3.66E-02 | 6 | P46527, Q9UM47, P16070, Q13315, P17252, Q02750 | CDKN1B, NOTCH3, CD44, ATM, PRKCA, MAP2K1 | More | | Oxyphenbutazone | hsa05210 | Colorectal cancer | 1.78E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | | Oxyphenbutazone | hsa05211 | Renal cell carcinoma | 1.06E-02 | 2 | Q06124, Q99814 | PTPN11, EPAS1 | More | | Oxyphenbutazone | hsa05212 | Pancreatic cancer | 5.76E-04 | 5 | P42338, P42224, P84022, Q13485, O75293 | PIK3CB, STAT1, SMAD3, SMAD4, GADD45B | More | | Oxyphenbutazone | hsa05214 | Glioma | 4.75E-02 | 3 | P0DP23, P19174, O75293 | CALM1, PLCG1, GADD45B | More | | Oxyphenbutazone | hsa05216 | Thyroid cancer | 3.80E-02 | 2 | P01106, O75293 | MYC, GADD45B | More | | Oxyphenbutazone | hsa05219 | Bladder cancer | 4.07E-02 | 2 | P14780, P04637 | MMP9, TP53 | More | | Oxyphenbutazone | hsa05220 | Chronic myeloid leukemia | 1.44E-03 | 6 | Q13547, Q13485, P25963, P84022, P42338, O75293 | HDAC1, SMAD4, NFKBIA, SMAD3, PIK3CB, GADD45B | More | | Oxyphenbutazone | hsa05222 | Small cell lung cancer | 2.38E-03 | 6 | Q13489, P10415, P25963, Q13077, O00463, P24522 | BIRC3, BCL2, NFKBIA, TRAF1, TRAF5, GADD45A | More | | Oxyphenbutazone | hsa05223 | Non-small cell lung cancer | 1.39E-02 | 3 | P10826, Q9HC35, O75293 | RARB, EML4, GADD45B | More | | Oxyphenbutazone | hsa05224 | Breast cancer | 4.75E-02 | 4 | P49841, Q92837, P04637, P24522 | GSK3B, FRAT1, TP53, GADD45A | More | | Oxyphenbutazone | hsa05226 | Gastric cancer | 2.78E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | | Oxyphenbutazone | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 2.74E-04 | 10 | O95267, P07766, P20963, P09693, P06239, O60603, Q04759, Q16539, Q9HC35, P01730 | RASGRP1, CD3E, CD247, CD3G, LCK, TLR2, PRKCQ, MAPK14, EML4, CD4 | More | | Oxyphenbutazone | hsa05310 | Asthma | 3.13E-03 | 3 | P13765, P12724, P01375 | HLA-DOB, RNASE3, TNF | More | | Oxyphenbutazone | hsa05321 | Inflammatory bowel disease | 1.20E-05 | 7 | O60603, P01375, P13765, Q14765, Q9UL17, P23771, Q9HBE5 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3, IL21R | More | | Oxyphenbutazone | hsa05322 | Systemic lupus erythematosus | 5.47E-06 | 15 | P08246, P08311, P09871, P01375, P10747, P13765, Q6FI13, Q93077, P62807, P33778, Q16778, O60814, P68431, P12814, P05455 | ELA2, CTSG, C1S, TNF, CD28, HLA-DOB, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, H2BC3, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, ACTN1, SSB | More | | Oxyphenbutazone | hsa05332 | Graft-versus-host disease | 5.67E-05 | 5 | P13765, P10747, P01375, P26715, Q13241 | HLA-DOB, CD28, TNF, KLRC1, KLRD1 | More | | Oxyphenbutazone | hsa05340 | Primary immunodeficiency | 1.28E-03 | 4 | P01730, P11912, P07766, P06239 | CD4, CD79A, CD3E, LCK | More | | Oxyphenbutazone | hsa05418 | Fluid shear stress and atherosclerosis | 1.26E-04 | 8 | Q16539, Q14145, P10599, P14780, P01375, P04637, P14778, P27930 | MAPK14, KEAP1, TXN, MMP9, TNF, TP53, IL1R1, IL1R2 | More | | |